Health Affairs' Editor-in-Chief Alan Weil interviews Jennifer Kao of the University of California Los Angeles on her recent paper that explores the impact of the Food and Drug Administration's breakthrough therapy designation program on the reduction of late-stage drug development time.
Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.
A Health Podyssey